Vivoryon Therapeutics N.V. (VIE:VVYN)

Austria flag Austria · Delayed Price · Currency is EUR
1.494
-0.020 (-1.32%)
At close: Feb 2, 2026
-23.38%
Market Cap42.94M -18.7%
Revenue (ttm)n/a
Net Income-12.48M
EPS-0.48
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume69
Open1.500
Previous Close1.514
Day's Range1.486 - 1.500
52-Week Range1.406 - 1.988
Betan/a
RSI35.74
Earnings DateApr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 14
Stock Exchange Vienna Stock Exchange
Ticker Symbol VVYN
Full Company Profile

Financial Performance

Financial Statements